Sienna Biopharma: Surges after Nasdaq panel allows it to remain listed

Sienna Biopharmaceuticals

14/11/2019 15:32

** Drug developer's  SNNA.O  shares more than double to 35
cents - stock's best day ever
    ** Company third-highest pct. gainer across U.S. exchanges
    ** Nasdaq panel allows company to remain listed on the
Nasdaq Stock Market - SNNA 
    ** Company's stock to remain conditionally listed during  
Chapter 11 bankruptcy asset sale process
    ** SNNA should update the panel on the results of the
Chapter 11 bankruptcy protection in Delaware - Nasdaq
    ** Company had filed for Chapter 11 bankruptcy protection in
Delaware in Sept, two years after going public  urn:newsml:reuters.com:*:nL3N26833E
    ** Including session's gain, stock is down ~86% so far this
year

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 0647;))